efraloctocog alfa

Efraloctocog alfa is a recombinant coagulation factor VIII Fc fusion protein indicated for the treatment and prophylaxis of bleeding in patients with hemophilia A (congenital factor VIII deficiency). It consists of a single molecule of B-domain deleted recombinant human coagulation factor VIII covalently linked to the Fc domain of human immunoglobulin G1 (IgG1). This fusion protein utilizes the naturally occurring neonatal Fc receptor (FcRn) recycling pathway to delay lysosomal degradation and extend the circulating half-life of the factor VIII protein, allowing for less frequent prophylactic dosing compared to standard factor VIII products. It was developed through a collaboration between Biogen and Sobi, with Sanofi subsequently acquiring rights in several territories through its acquisition of Bioverativ.

Brand names

EloctateElocta

Other names

rFVIIIFcRecombinant Factor VIII Fc Fusion Protein